Contributed Abstracts
Hall 1 (Salt Palace Convention Center)
Conditioning Therapy by TBI and Etoposid Causing High Rate of Acute Kidney Injury in ALL Allogenetic Stem Cell Transplantation in Children
Samuel Abbou, Robert Debré hospital;
Mony Fahd, Robert Debré hospital;
Frederique Duquesne, Robert Debré hospital;
Thomas Bontant, Robert Debré hospital;
Saba Azarnoush, Robert Debré hospital;
Karima Yakouben, Robert Debré hospital;
Benoit Brethon, Robert Debré hospital;
Marie ouachée Chardin, Robert Debré hospital;
Andre Baruchel, MD, Robert Debré hospital;
Jean-Hughes Dalle, Hopital Robert Debre
Micafungin Followed by Posaconazole Is Effective As Primary Antifungal Prophylaxis in First Three Months After Unrelated Donor Transplantation
Naheed Alam, MBBS, Princess Margaret Hospital, University of Toronto;
Coleman Rotstein, MD, University of Toronto;
Eshetu Atenafu, Princess Margaret Hospital;
Vikas Gupta, MD, FRCP, FRCPath, Princess Margaret Hospital, University of Toronto;
Dennis Kim, Princess Margaret Hospital, University of Toronto;
Hans Messner, MD, PhD, Princess Margaret Hospital, University of Toronto;
John Kuruvilla, MD, Princess Margaret Hospital, University of Toronto;
Jeffrey H Lipton, MD, PhD, Princess Margaret Hospital, University of Toronto
Nocardiosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Matched Case-Control Study of Risk Factors, Clinical Features and Outcomes
Nadia M Bambace, MD, FRCPC, Hematology/Stem Cell Transplantation, Maisonneuve Rosemont / University of Montreal, Montreal, QC, Canada;
Louise Poirier, MD, FRCPC, Maisonneuve Rosemont/University of Montreal;
Sandra Cohen, MD, FRCPC, Maisonneuve Rosemont / University of Montreal;
Thomas Kiss, MD, FRCPC, Hematology/Stem Cell Transplantation, Maisonneuve Rosemont / University of Montreal, Montreal, QC, Canada;
Guy Sauvageau, MD, PhD, FRCPC, Inst De Recherches, Clinic De Montreal;
Jean Roy, MD, FRCPC, Hematology/Stem Cell Transplantation, Maisonneuve Rosemont / University of Montreal, Montreal, QC, Canada;
Denis-Claude Roy, MD, FRCPC, Hematology/Stem Cell Transplantation, Maisonneuve Rosemont / University of Montreal, Montreal, QC, Canada;
Miguel Chagnon, M.SC., P.Stat., Université de Montréal;
Silvy Lachance, MD, FRCPC, Hematology/Stem Cell Transplantation, Maisonneuve Rosemont / University of Montreal, Montreal, QC, Canada
Significance of Rh Mismatch in Allogeneic Hematopoietic Progenitor Cell Transplants
Sara M Barnes, Mayo Clinic;
Craig Tauscher, Mayo Clinic;
Brenda J Bendix, Mayo Clinic;
Sarah Wittwer, Mayo Clinic;
Sandra Bryant, Mayo Clinic;
James R. Stubbs, M.D., Mayo Clinic;
Dennis Gastineau, MD, Mayo Clinic;
Eapen K Jacob, M.D., Mayo Clinic
The Cost of Pediatric Unrelated HSCT
Daniele Porto Barros, RN, Instituto de Oncologia Pediátrica;
Adriana Seber, MD, Instituto de Oncologia Pediatrica;
Valéria Cortez Ginani, MD, Instituto de Oncologia Pediátrica - GRAACC - Unifesp;
Carmen Vergueiro, MD, Associação da Medula Óssea - AMEO;
Adriane Ibanez, RN, Instituto de Oncologia Pediátrica - GRAACC - Unifesp;
Olga Margareth Wanderley de Oliveira Felix, MS, Instituto de Oncologia Pediátrica;
Roseane Gouveia, MD, Instituto de Oncologia Pediatrica;
Fernando Domingues, Instituto de ONcologia Pediátrica - GRAACC - Unifesp;
Luciana Antunes, Instituto de Oncologia Pediátrica - GRAACC - Unifesp;
Valeria Oliveira, Instituto de Oncologia Pediátrica - GRAACC - Unifesp
Allogeneic Hematopoietic Stem Cell Transplant in Patients Older Than 50 Years. Experience of Four Argentinean Centers
Mariano Berro, MD, Hospital Universitario Austral;
Viviana Montes de Oca, MD, Hospital Universitario Austral;
Maria Rivas, MD, Hospital Universitario Austral;
Ana Lisa Basquiera, Hospital Privado de Cordoba;
Gregario Jaimovich, MD, Fundacion Favaloro;
Juliana Martinez Rolon, MD, Fundaleu;
Alejandro Requejo, MD, Fundacion Favaloro;
Juan Garcia, MD, Hospital Privado de Cordoba;
Gustavo Kusminsky, MD, Hospital Universitario Austral
Sequence-Based Discovery of Novel Bacteria, Bradyrhizobium Enterica, in Cord Colitis Syndrome
Ami S. Bhatt, MD, PhD, Broad Institute;
Sam Freeman, Broad Institute;
Alex Herrera, MD, Dana-Farber Cancer Institute;
Chandra Sekhar Pedamallu, PhD, Dana-Farber Cancer Institute;
Dirk Gevers, PhD, Broad Institute;
Joonil Jung, PhD, Broad Institute;
Fujiko Duke, Broad Institute;
Sarah Young, PhD, Broad Institute;
Ashlee Earl, PhD, Broad Institute;
Aleksandar Kostic, Dana-Farber Cancer Institute;
Akinyemi Ojesina, MD, PhD, Broad Institute;
Gabriela Soriano, MD, Memorial Sloan-Kettering Cancer Center;
Bruce J. Walker, Broad Institute;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Joseph H Antin, MD, Dana-Farber Cancer Institute;
Lindsey Baden, MD, Brigham and Women's Hospital;
Jason Hornick, MD, PhD, Brigham and Women's Hospital;
Francisco Marty, MD, Dana-Farber Cancer Institute;
Matthew Meyerson, MD, PhD, Dana-Farber Cancer Institute
An Identical Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic (allo) Hematopoietic Stem Cell Transplantation (HSCT) in 222 Patients with Hematologic Malignancies: A Monocenter Experience
Didier Blaise, MD, Institut Paoli Calmettes;
Luca Castagna, Institut Paoli-Calmettes;
Geoffroy Venton, Institut Paoli-Calmettes;
Roberto Crocchiolo, Institut Paoli-Calmettes;
Jean EL-Cheikh, Institut Paoli-Calmettes;
Sabine Furst, MD, Institut Paoli Calmettes;
Claire Oudin, Institut Paoli-;
Angela Granata, Institut Paoli-Calmettes;
Norbert Vey, Institut Paoli-Calmettes;
Réda Bouabdallah, Institut Paoli-Calmettes;
Christian Chabannon, MD, PhD, Institut Paoli Calmettes
Post-Transplant Outcome in Patients with Acute Myeloid Leukemia and Myelodysplasic Syndrome Who Received Conditioning Regimen Based On Fludarabin, Busulfan and Anti-Thymoglobulin Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Didier Blaise, MD, Institut Paoli Calmettes;
Claire Oudin, Institut Paoli-Calmettes;
Patrice Chevallier, CHU NANTES;
Sabine Furst, MD, Institut Paoli Calmettes;
Thierry Guillaume, University of Louvain;
Jean EL-Cheikh, Institut Paoli-Calmettes;
Roberto Crocchiolo, Institut Paoli-Calmettes;
J. Delaunay, Institut Paoli-;
Anne Etienne, Institut Paoli-Calmettes;
Norbert Vey, Institut Paoli-Calmettes;
Mohamad Mohty, CHU de Nantes - Hotel-Dieu
Reduced Intensity Transplants Using G-CSF-Mobilized Hemopoietic CELLS From Haploidentical Related Donors
Kenneth Bradstock, BSc MB BS PhD, Westmead Hospital;
John Kwan, MB BS FRACP FRCPA, Westmead Hospital;
Kenneth Micklethwaite, MBBS, BSc, PhD, FRACP, FRCPA, Westmead Hospital;
David Gottlieb, MD PhD, University of Sydney;
Emily Blyth, MB BS PHD FRACP, Westmead Hospital;
Gillian Huang, Westmead Hospital;
Stephanie Deren, RN, Westmead Hospital;
Mark Hertzberg, MBBS PhD FRACP FRCPA, Westmead Hospital
Outcome of Hematopoietic Cell Transplant for Hemophagocytic Lymphohistiocytosis in Adults: A Single Center Experience
Shanmuganathan Chandrakasan, MD, Cincinnati Children's Hospital Medical Center;
Rebecca A Marsh, MD, Cincinnati Children's Hospital Medical Center;
Denise Bellman, Cincinnati Children's Hospital Medical Center;
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center;
Jack Bleesing, MD, PhD, Cincinnati Children's Hospital Medical Center;
Michael Jordan, MD, Cincinnati Children's Hospital Medical Center;
Stella M. Davies, MBBS, PhD, Cincinnati Children's Hospital Medical Center;
Alexandra Filipovich, MD, Cincinnati Children's Hospital Medical Center
Same Sibling Marrow Following Cord Allogeneic Transplantation As Therapy for Second Relapse APL: A Pediatric Case Report
Satiro De Oliveira, MD, David Geffen School of Medicine at UCLA;
Andrew Pham, David Geffen School of Medicine at UCLA;
Berkley Brown, NP, Mattel Children's Hospital-UCLA Medical Center;
LaMarr Taylor Smith, CCRP, Mattel Children's Hospital-UCLA Medical Center;
Pamela Kempert, MD, David Geffen School of Medicine at UCLA;
Theodore B Moore, MD, David Geffen School of Medicine at UCLA
Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia with Busulfan-Based Reduced Intensity Conditioning: Cure and Fertility
David Dennison, MBBS, MD, Sultan Qaboos University Hospital;
Khalil Al Farsi, MD, FRCPC, Sultan Qaboos University Hospital;
Mohammed Al Huneini, MD, Sultan Qaboos University Hospital;
Murtadha Al Khabori, M.D, FRCPC, Sultan Qaboos University Hospital;
Abdulhakeem Rawas, MD, Sultan Qaboos University Hospital;
Maryam Al Shukri, MD, Sultan Qaboos University Hospital;
Shoaib Al Zadjali, PhD, Sultan Qaboos University Hospital;
Melanie Tauro, MSc, Sultan Qaboos University Hospital;
Rhea Misquith, BSc, Sultan Qaboos University Hospital;
Arwa Z Al Riyami, MD, FRCPC, Sultan Qaboos University Hospital;
Pathare Anil, MD, Sultan Qaboos University Hospital;
Yusra Al Habsi, BSc (Nursing), Sultan Qaboos University Hospital;
Aqeela Al Lawati, MSc (Pharmacy), Sultan Qaboos University Hospital;
Rahma Al Mahrizi, BSc (Nursing), Sultan Qaboos University Hospital;
Rajagopal Krishnamoorthy, PhD, Hospital Robert Debre;
Salam Al Kindi, MD, Sultan Qaboos University Hospital
Reconstitution of Lymphocyte Subsets and Outcomes After Matched and Mismatched Hematopoietic Stem-Cell Transplantation
Antonio di Stasi, MD, MDACC;
Michelle Poon, MD, The University of Texas MD Anderson Cancer Center;
Amir Hamdi, MD, The University of Texas MD Anderson Cancer Center;
Hila Shaim, MDACC;
Susan Xie, MDACC;
Denai Milton, MDACC;
Roland Bassett Jr., MS, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Laurence J.N. Cooper, MD, PhD, UT MDACC;
Dean A. Lee, MD, PhD, University of Texas MD Anderson Cancer Center;
Katayoun Rezvani, MD; PhD, MD Anderson Cancer Center;
Richard E. Champlin, MD, MD Anderson Cancer Center;
Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center
Immune Modulation of Antibody Responses Induced Through Allogeneic Cell Transplantation
Raimon Duran-Struuck, DVM, PhD, Massachusetts General Hospital;
Mihail Climov, MD, Harvard Medical School;
Ashley Gusha, Massachusetts General Hospital;
Edward Harrington, Massachusetts General Hospital;
Abraham J. Matar, University of Central Florida College of Medicine;
Rebecca L. Crepeau, Massachusetts General Hospital;
Thomas R. Spitzer, MD, Massachusetts General Hospital;
David H. Sachs, MD, Massachusetts General Hospital;
Christene A. Huang, PhD, Massachusetts General Hospital
The MGH Miniature Swine As a Large Animal Model of HCT and Graft Versus Host Disease
Raimon Duran-Struuck, DVM, PhD, Massachusetts General Hospital;
George F. Murphy, MD, Brigham & Women's Hospital;
Roderick T. Bronson, DVM, Harvard Medical School;
David H. Sachs, MD, Massachusetts General Hospital;
Christene A. Huang, PhD, Massachusetts General Hospital;
Thomas R. Spitzer, MD, Massachusetts General Hospital
Pre-Transplant Therapy for Patients with Myelodysplastic Syndrome and Post-Transplant Outcome
Shatha Farhan, Henry Ford Hospital;
Rick McKinnon, BS MT, Henry Ford Hospital;
Sarah Szymanski, Henry Ford hospital;
Klodiana Neme, PharmD, Henry Ford Hospital;
Nancy Mikulandric, PharmD, Henry Ford Hospital;
Edward Peres, Henry Ford hospital;
Nalini Janakiraman, MD, Henry Ford Health Systems
The Serum Galactomannan Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Probable Pulmonary Invasive Aspergillosis
Cynthia E Fisher, MD, MPH, University of Washington;
Anne Stevens, Fred Hutchinson Cancer Research Center;
Michael J. Boeckh, MD, Fred Hutchinson Cancer Research Center;
Wendy Leisenring, Fred Hutchinson Cancer Research Center;
Steven A. Pergam, MD, MPH, Fred Hutchinson Cancer Research Center;
Tobias Hohl, MD, PhD, Fred Hutchinson Cancer Research Center
Impact of CD 34 Cell Dose and Conditioning Regimens On Donor T-Cell and Myeloid Chimerism After an Alemtuzumab-Based in-Vivo T-Cell Depleted Allogeneic Stem Cell Transplant (SCT)
Henry C Fung, MD, Rush University Medical Center;
John Maciejewski, MD, PhD, Rush University Medical Center;
Lela Buckingham, PhD, Rush University Medical Center;
Muhammed Alikhan, Rush University Medical Center;
Shruthi Melinamani, Rush University Medical Center;
Reem Karmali, MD, Rush University Medical Center;
Elizabeth Rich, MD, PhD, Rush University Medical Center;
Parameswaran Venugopal, MD, Rush University Medical Center;
Stephanie A. Gregory, MD, Rush University Medical Center;
Sunita Nathan, MD, Rush University Medical Center
Hematopoietic STEM CELL Transplantation in Myelofibrosis: A Comparison Between Myeloablative and Reduced Intensity Conditioning
Vaneuza Araujo Moreira Funke Sr., MD, MS, Universidade do Parana - UFPR;
Vanessa Fiorini Furtado Jr., studant, Federal University of Parana;
Gustavo Rengel Santos, studant, Federal University of Parana;
Leticia A Sinamura Jr., studant, Federal University of Parana;
Tamila Fagundes Jr., studant, Federal University of Parana;
Daniela C. Setubal, MD, Federal University of Parana;
Caroline Sola, Hospital De Clinicas Da Ufpr;
Elenaide Coutinho Nunes Sr., MD, Nossa Senhora das Graças Hospital;
Ricardo Pasquini, MD, Federal University of Parana;
Michel Michels Oliveira, MD, Federal University of Parana;
Samir Nabhan Jr., MD, Federal University of Parana;
Larissa Medeiros Jr., MD, Hospital Nossa Senhora das Gracas;
Mariester Malvezzi, MD. MS, Federal University of Parana
Risk Factors for Prolonged Length of Hospitalization in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Betty Ky Hamilton, MD, Cleveland Clinic Taussig Cancer Institute;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Brian Bolwell, MD, Cleveland Clinic Taussig Cancer Institute;
Matt E. Kalaycio, MD, Cleveland Clinic Taussig Cancer Institute;
Mikkael Sekeres, MD, Cleveland Clinic Taussig Cancer Institute;
Ronald Sobecks, MD, Cleveland Clinic Taussig Cancer Institute;
Rabi Hanna, MD, Cleveland Clinic Foundation;
Robert M Dean, MD, Cleveland Clinic Taussig Cancer Institute;
Hien Duong, MD, Cleveland Clinic Taussig Cancer Institute;
Brian Hill, MD, PhD, Cleveland Clinic Taussig Cancer Institute;
Edward A. Copelan, MD, Levine Cancer Institute
Cytomegalovirus Viremia Is a Risk Factor for Late-Onset Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation
Ting-ting Han, MD, Peking University People's Hospital;
Lan-ping Xu, MD, Peking University People's Hospital;
Dai-hong Liu, MD, Peking University People's Hospital;
Kai-yan Liu, MD, Peking University People's Hospital;
Hai-xia Fu, MD, Peking University People's Hospital;
Xiao-jun Huang, MD, Peking University People's Hospital
Retrospective Survey of Hemostatic Complications in 680 Patients Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)
Yue Han, the First Affiliated Hospital of Soochow University;
Luping Hu, the First Affiliated Hospital of Soochow University;
Yongya Ren, the First Affiliated Hospital of Soochow University;
Wei Zhang, the First Affiliated Hospital of Soochow University;
Aining Sun, the First Affiliated Hospital of Soochow University;
Zhaoyue Wang, the First Affiliated Hospital of Soochow University;
Changgeng Ruan, the First Affiliated Hospital of Soochow University;
Depei Wu, the First Affiliated Hospital of Soochow University
Predictive Classification of Chronic Gvhd Status by Immune Reconstitution Testing
Shernan Holtan, MD, Oregon Health & Science University;
Laura F Newell, MD, Oregon Health & Science University;
Gabrielle Meyers, MD, Oregon Health & Science University;
Andy I. Chen, MD, PhD, Oregon Health & Science University;
Brandon Hayes-Lattin, MD, Oregon Health & Science University;
James Gajewski, MD, FACP, Oregon Health & Science University;
Susan Slater, FNP, Oregon Health & Science University;
Eneida Nemecek, MD, Oregon Health & Science University;
Rita Braziel, MD, Oregon Health & Science University;
Guang Fan, MD, PhD, Oregon Health & Science University;
Richard T. Maziarz, MD, Oregon Health & Science University;
Nicky Leeborg, MD, Oregon Health & Science University
Hypomethylating Agents for Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Annie Im, MD, University of Pittsburgh Cancer Institute;
Anastasios Raptis, MD, PhD, UPMC Cancer Centers;
Jing-Zhou Hou, MD, UPMC Cancer Centers;
Cheryl Tompkins, RN, MSN , CRNP, UPMC Cancer Centers;
Melissa Loucks, PA, UPMC Cancer Centers;
Mary Guay, PA-C, Indiana University;
Julie Phillips, MSN CRNP, UPMC Cancer Centers;
Michael Boyiadzis, MD, University of Pittsburgh Cancer Institute;
Mounzer Agha, MD, UPMC Cancer Centers
Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Is Predictive of Serious Adverse Events and Overall Survival in Older Allogeneic Transplant Recipients
Jesse W Keller, MD, University of California San Francisco;
Lloyd E Damon, MD, University of California San Francisco;
Lawrence D Kaplan, MD, University of California San Francisco;
Thomas G Martin, University of California San Francisco;
Jeffrey L Wolf, MD, University of California San Francisco;
Weiyun Z Ai, MD PhD, University of California San Francisco;
Charalambos Andreadis, MD, MSCE, University of California San Francisco;
Jeffrey M Venstrom, MD, University of California San Francisco;
Catherine C Smith, MD, University of California San Francisco;
Karin ML Gaensler, MD, University of California San Francisco;
Jimmy Hwang, PhD, University of California San Francisco;
Rebecca L Olin, MD, MSCE, University of California San Francisco
Outcomes of Hematopoietic Cell Transplantation in Ethnic and Racial Minorities
Nandita Khera, MD, Mayo Clinic Arizona;
Amylou Dueck, PhD, Mayo Clinic in Arizona;
James Slack, MD, Mayo Clinic Arizona;
Veena Fauble, MD, Mayo Clinic Arizona;
Lisa Ostrosky Sproat, MD, MSW, Mayo Clinic Arizona;
Roberta Adams, MD, Mayo Hospital;
Jose Leis, MD, PhD, Mayo Clinic Arizona;
Jared Klein, MD, Mayo Clinic in Arizona;
Pierre Noel, MD, Mayo Clinic Arizona;
Joseph Mikhael, MD, MEd, FRCPC, Mayo Clinic in Arizona
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using Fludarabine, Reduced-Dose Cyclophosphamide, and ATG
Sumiko Kohashi, MD, Keio University School of Medicine;
Takehiko Mori, MD, PhD, Keio University School of Medicine;
Jun Kato, MD, Keio University School of Medicine;
Akiko Yamane, MD, PhD, Keio University School of Medicine;
Shinichiro Okamoto, MD, PhD, Keio University School of Medicine
The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Following Liver Transplantation in Children with Immunodeficiencies
Z Yesim Kucuk, MD, Cincinnati Children's Hospital Medical Center;
Stella M. Davies, MBBS, PhD, Cincinnati Children's Hospital Medical Center;
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center;
Sonata Jodele, MD, Cincinnati Children's Hospital Medical Center;
Michael Jordan, MD, Cincinnati Children's Hospital Medical Center;
Ashish Kumar, MD, PhD, Cincinnati Children's Hospital Medical Center;
Rebecca A Marsh, MD, Cincinnati Children's Hospital Medical Center;
Parinda A. Mehta, MD, Cincinnati Children's Hospital Medical Center;
Kasiani Myers, MD, Cincinnati Children's Hospital Medical Center;
Mario H Alonso, MD, Cincinnati Children's Hospital Medical Center;
Gregory M Tiao, MD, Cincinnati Children's Hospital Medical Center;
John C Bucuvalas, MD, Cincinnati Children's Hospital Medical Center;
Samuel Kocoshis, MD, Cincinnati Children's Hospital Medical Center;
Nada Yazigi, MD, Cincinnati Children's Hospital Medical Center;
Jack Bleesing, MD, PhD, Cincinnati Children's Hospital Medical Center;
Alexandra Filipovich, MD, Cincinnati Children's Hospital Medical Center
Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation
Ghada M Kunter, MD, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida;
Janelle Perkins, PharmD, Moffitt Cancer Center;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center;
Frederick Locke, H. Lee Moffitt Cancer Center;
Teresa Field, MD PhD, H. Lee Moffitt Cancer Center;
Joseph Pidala, MD, MS, Moffitt Cancer Center;
Lia Perez, H. Lee Moffitt Cancer Center;
Mohamed Kharfan-Dabaja, H. Lee Moffitt Cancer Center;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center
BK Polyoma Virus (BKV) and Hemorrhagic Cystitis (HC) Post Allogenic Stem Cell Transplant (HSCT): A Prospective Study in a Cohort From Different Stem Cell Sources
Yeon Joo Lee, MD, MPH, Memorial Sloan-Kettering Cancer Center;
Junting Zheng, MS, Memorial Sloan-Kettering Cancer Center;
Dick Chung, Memorial Sloan-Kettering Cancer Center;
Isabella Amigues, MD, Memorial Sloan-Kettering Cancer Center;
Tammy Son, Memorial Sloan-Kettering Cancer Center;
Kathy Choo, RN, MSN, OCN, Memorial Sloan-Kettering Cancer Center;
Cesar Figueroa, MD, Memorial Sloan-Kettering Cancer Center;
Jeff Hester, PhD, Viracor - IBT Laboratories;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, PhD MD, Memorial Sloan-Kettering Cancer Center;
Genovefa Papanicolaou, MD, Memorial Sloan-Kettering Cancer Center
The Impact of Comorbidity, Performance Status and Insurance Coverage in Patients Undergoing Myeloablative Allogeneic Transplant
Amy Liu, University of Oklahoma;
Jennifer Steward, Univeristy of Oklahoma;
Donald Harrison, Ph.D., FAPhA, University of Oklahoma;
Mohamad Khawandanah, M.D., University of Oklahoma - Peggy and Charles Stephenson Cancer Center;
Meredith Moorman, PharmD, Duke University Medical Center;
George Selby, M.D., The University of Oklahoma Health Sciences Center;
Jennifer Holter Chakrabarty, M.D., University of Oklahoma -Peggy and Charles Stephenson Cancer Center
A Novel Intermediate Alemtuzumab Schedule Optimizes the Incidences of Mixed Chimerism and Acute Gvhd in Patients with HLH and XLP Undergoing Allogeneic HCT
Rebecca A Marsh, MD, Cincinnati Children's Hospital Medical Center;
Mi-Ok Kim, Cincinnati Children's Hospital Medical Center;
Denise Bellman, Cincinnati Children's Hospital Medical Center;
Laura Hart, Cincinnati Children's Hospital Medical Center;
Michael B. Jordan, MD, Cincinnati Children's Hospital Medical Center;
Jack Bleesing, MD, PhD, Cincinnati Children's Hospital Medical Center;
Parinda A. Mehta, MD, Cincinnati Children's Hospital Medical Center;
Sonata Jodele, MD, Cincinnati Children's Hospital Medical Center;
Kasiani Myers, MD, Cincinnati Children's Hospital Medical Center;
Ashish Kumar, MD, PhD, Cincinnati Children's Hospital Medical Center;
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center;
Stella M. Davies, MBBS, PhD, Cincinnati Children's Hospital Medical Center;
Alexandra Filipovich, MD, Cincinnati Children's Hospital Medical Center
The Management of Relapsed AML or MDS Following a T-Cell Depleted Allogeneic Stem Cell Transplant
Ewelina Morawa, MD, Memorial Sloan-Kettering Cancer Center;
Emily Zabor, MS, Memorial Sloan-Kettering Cancer Center;
Molly Maloy, BA, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center
BK Virus by PCR From Peripheral Blood At Day 21 After Allogeneic Transplant Predicts Risk for Hemorrhagic Cystitis
Jaime Anne Hilger Mullin, DO, Western Pennsylvania Cancer Institute;
Tatyana Sklyar, MD, WPAHS;
Sushil Ratnaparkhe, MD, WPAHS;
Tarik Hadid, MD, Western Pennsylvania Cancer Institute;
Gina Berteotti, Western Pennsylvania Cancer Institute;
John Lister, MD, Western Pennsylvania Cancer Institute;
Entezam Sahovic, MD, Western Pennsylvania Cancer Institute
Impact of Iron Overload On Immune Function for Patients Undergoing Allogeneic Transplants for Hematologic Disorders: Results of Pilot Study
Seema Naik, MD, Wake Forest Baptist Medical Center;
Ralph D'Agostino Jr., PhD, Wake Forest Baptist Medical Center;
Mary Ann Knovich, MD, Wake Forest Baptist Medical Center;
David Grier, MD, Wake Forest Baptist Medical Center;
Robin Harrelson, RN, BSN, OCN, Wake Forest Baptist Medical Center;
Linda McPhail, PhD, Wake Forest University Health Sciences
The Prognostic Significance of Peripheral Blood Mixed Chimerism After T-Cell Depleted Allogeneic Stem Cell Transplant
Amanda L. Olson, MD, Memorial Sloan-Kettering Cancer Center;
Rachel Lehrman, BS, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Molly Maloy, BA, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, MD, Memorial Sloan-Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Jenna Goldberg, MD, Memorial Sloan-Kettering Cancer Center;
Richard O'Reilly, MD, Memorial Sloan-Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, PhD MD, Memorial Sloan-Kettering Cancer Center
Intramural Duodenal Haematoma After Upper Gastrointestinal Endoscopic Biopsy in a Bone Marrow Transplant Recipient
Tulay Ozcelik, Associate Professor, Sisli Florence Nightingale Hospital;
Fehmi Hindilerden, Assistant Professor, Sisli Florence Nightingale Hospital;
Baris Hasbal, MD, Sisli Florence Nightingale Hospital;
Murat Akyildiz, Associate Professor, Sisli Florence Nightingale Hospital;
Murat Dayangac, MD, Sisli Florence Nightingale Hospital;
Refik Killi, Professor, Sisli Florence Nightingale Hospital;
Mutlu Arat, Professor, Sisli Florence Nightingale Hospital
BK Virus-Associated Nephropathy (BKVN), an Under-Recognized Cause of Renal Dysfunction in Severely Immunosuppressed Hematopoietic Stem Cell Transplant (HSCT) Patients: Report of 5 Cases of Bkvn and the Potential Role of CMX001 for Treatment
Genovefa Papanicolaou, MD, Memorial Sloan-Kettering Cancer Center;
Yovanna Kolitsopoulos, BS, Memorial Sloan Kettering Cancer Center;
James Young, MD, FACP, Memorial Sloan-Kettering Cancer Center;
Adam Boruchov, MD, University of Connecticut School of Medicine;
Niranjan Sankaranarayanan, MD, University of Connecticut School of Medicine;
David Hull, MD, University of Connecticut School of Medicine;
Ilya Glezerman, MD, Memorial Sloan Kettering Cancer Center;
Herve Mommeja-Marin, MD, Chimerix, Inc.
Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study
Simrit Parmar, MD, UT MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Marcos de Lima, UT MD Anderson Cancer Center;
Peter Thall, UT MD Anderson Cancer Center;
Roland Bassett Jr., MS, The University of Texas MD Anderson Cancer Center;
Paolo Anderlini, MD, UT MD Anderson Cancer Center;
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, MD Anderson Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center
Assessment of a Disease Risk Index in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Fludarabine and Pharmacokinetically Dose-Targeted Intravenous Busulfan: Effect On Overall and Progression-Free Survival
Janelle Perkins, PharmD, H. Lee Moffitt Cancer Center;
Teresa Field, MD PhD, H. Lee Moffitt Cancer Center;
Frederick Locke, H. Lee Moffitt Cancer Center;
Mohamed Kharfan-Dabaja, H. Lee Moffitt Cancer Center;
Ernesto Ayala, H. Lee Moffitt Cancer Center;
Marcie Tomblyn, MD, MS, H. Lee Moffitt Cancer Center;
Joseph Pidala, MD, MS, H. Lee Moffitt Cancer Center;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center
Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)
Galena Salem, MD, Ohio State University;
Amy S. Ruppert, MAS, Ohio State University Medical Center;
Patrick Elder, MS, Arthur G. James Cancer Institute;
Craig C Hofmeister, MD, Ohio State University Medical Center;
Don M Benson, MD, PhD, The Ohio State University;
Sam Penza, MD, The Ohio State University;
Leslie A Andritsos, MD, The Ohio State University;
Rebecca Klisovic, MD, Ohio State University Medical Center;
Sumithira Vasu, MBBS, Ohio State University Medical Center;
William Blum, MD, The Ohio State University;
Steven M Devine, MD, The Ohio State University;
Samantha Jaglowski, MD, Ohio State University Medical Center;
Yvonne Efebera, MD, The Ohio State University
Soluble Aminopeptidase N (CD13) Is a Diagnostic Biomarker of Late-Onset Chronic Graft Vs. Host Disease in Adults
Sabine Ivison, PhD, University of British Columbia;
Amina Kariminia, PhD, University of British Columbia;
Barry Storer, PhD, Fred Hutchinson Cancer Research Center;
Robert McMaster, PhD, University of British Columbia;
John A. Hansen, MD, Fred Hutchinson Cancer Research Center;
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center;
Kirk R. Schultz, MD, BC Children's Hospital/UBC
Long-Term Survival After Allogeneic Haematopoietic Cell Transplantation for Acute Myeloid Leukemia. Comparable Results From Myeloablative and Non-Myeloablative Conditioning in Young and Elderly Patients
Henrik Sengelov, MD, National University Hospital, Rigshospitalet;
Thomas Gerds, PhD, University of Copenhagen;
Peter Braendstrup, MD, The Allo-HCT laboratory;
Brian Kornblit, MD, The Allo-HCT laboratory;
Bo Kok Mortensen, MD, The Allo-HCT laboratory;
Soren Petersen, MD, National University Hospital, Rigshospitalet;
Lars Vindeloev, MD, The Allo-HCT laboratory
Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (AlloHCT)
Nirali Shah, MD, National Cancer Institute/National Institutes of Health;
Michael J Borowitz, MD, PhD, Johns Hopkins Hospital;
Nancy Robey, PA, Johns Hopkins Hospital;
Christopher Gamper, MD, PhD, Johns Hopkins Hospital;
Heather Symons, MD, Johns Hopkins Hospital;
David Loeb, MD, PhD, Johns Hopkins Hospital;
Alan S Wayne, MD, National Cancer Institute/National Institutes of Health;
Allen Chen, MD, PhD, MHS, Johns Hopkins Hospital
Primary Hemophagocytic Lymphohistiocytosis and Hematopoeitic Stem Cell Transplantation in Iran
BibiShahin Shamsian, Department of Pediatric Hematology-Oncology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran;
Nima Rezaei, Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran;
Samin Alavi, Department of Pediatric Hematology-Oncology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran;
Mona Hedayat, Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran;
Mohammad Aminasnafi, Department of Pediatric Hematology-Oncology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;
Zahra Pourpak, Immunology, Asthma, and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran;
Atoosa Gharib, Department of Pediatric Pathology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;
Farzaneh Jadali, Department of Pediatric Pathology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;
Mohammad Taghi Arzanian, Department of Pediatric Hematology-Oncology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome
Connie Sizemore, PharmD, The Blood and Marrow Transplant Program at Northside Hospital;
Asad Bashey, MD PhD, The Blood and Marrow Transplant Program at Northside Hospital;
Lawrence Morris, MD, The Blood and Marrow Transplant Program at Northside Hospital;
Scott R. Solomon, MD, The Blood and Marrow Transplant Program at Northside Hospital;
Xu Zhang, PhD, Ga State University Mathematics;
H. Kent Holland, MD, The Blood and Marrow Transplant Program at Northside Hospital
Incidence of Invasive Fungal Disease After Unmanipulated Haploidentical Stem Cell Transplantation Was Significantly Higher Than That After HLA-Matched Sibling Transplantation
Yu-qian Sun, MD, Peking University People's Hospital;
Lan-ping Xu, MD, Peking University People's Hospital;
Dai-hong Liu, MD, Peking University People's Hospital;
Xiao-hui Zhang, MD, Peking University People's Hospital;
Wei Han, MD, Peking University People's Hospital;
Yu Wang, MD, Peking University People's Hospital;
Huan Chen, MD, Peking University People's Hospital;
Yu-hong Chen, MD, Peking University People's Hospital;
Feng-rong Wang, MD, Peking University People's Hospital;
Jing-zhi Wang, MD, Peking University People's Hospital;
Yu Ji, MD, Peking University People's Hospital;
Fei-fei Tang, MD, Peking University People's Hospital;
Kai-yan Liu, MD, Peking University People's Hospital;
Xiao-jun Huang, MD, Peking University People's Hospital
Feasibility of Low Dose Azacitidine Post T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants in Patients with Myeloid Malignancies At High Risk for Relapse
Roni Tamari, Memorial Sloan-Kettering Cancer Center;
Doris Ponce, MD, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, PhD MD, Memorial Sloan-Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
James Young, MD, FACP, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, MD, Memorial Sloan-Kettering Cancer Center
Allograft Leukocyte Content and Post-Allogeneic Hematopoietic Cell Transplant Lymphopenia and Monocytopenia
Mary Thoma, Physician Asst, MS, Mayo Clinic;
Jennifer Glejf, Mayo Clinic Arizona;
Eapen K Jacob, M.D., Mayo Clinic;
Tanya Huneke, Mayo Clinic Arizona;
Lori DeCook, Mayo Clinic Arizona;
Nicci Johnson, Mayo Clinic Arizona;
Mrinal Patnaik, MD, Mayo Clinic;
Mark Litzow, MD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Luis Porrata, Mayo Clinic;
Shernan Holtan, MD, Mayo Clinic
Survival After Second Allogeneic Transplant Is Improved in Recipients by Using the Original Donor
Waseem Touma, MD, Washington University School of Medicine;
Mark A. Schroeder, MD, Washington University School of Medicine;
Ningying Wu, PhD, Washington University School of Medicine;
Keith Stockerl-Goldstein, MD, Washington University School of Medicine;
Peter Westervelt, MD, PhD, Washington University School of Medicine;
John F. DiPersio, MD, PhD, Washington University School of Medicine;
Ravi Vij, MD, Washington University School of Medicine
Haploidentical Donor Transplantations with TLI, Fludarabine, Cyclophosphamide, and ATG Are Safe and Effective Treatment for Graft Failure
Brandon Matthew Triplett, MD, St Jude Childrens Research Hospital;
Mari Hashitate Dallas, MD, St. Jude Children's Research Hospital;
Christine Mary Hartford, MD, St. Jude Childrens Research Hospital;
Asha Pillai, BS, MD, St. Jude Children's Research Hospital;
David Shook, MD, St. Jude Children's Research Hospital;
Ashok Srinivasan, MD, St.Jude Children's Research Hospital;
Wing Leung, MD, PhD, St. Jude Children's Research Hospital
Dendritic Cell Activation in Allogeneic Haematopoietic Cell Transplantation: A Promising Target for Diagnosis and Therapy
Derek NJ Hart, MB ChB, PhD, ANZAC Research Institute;
Nirupama D. Verma, PhD, ANZAC Research Institute;
Georgina J. Clark, PhD, ANZAC Research Institute;
Phillip D. Fromm, PhD, ANZAC Research Institute;
Kifah Shahin, BSc, MS, PhD, Westmead Hospital;
Stephen Larsen, MD PhD, Royal Prince Alfred Hospital;
Kenneth Bradstock, BSc MB BS PhD, Westmead Hospital
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Refractory/Relapsed Acute Leukemia
Yu Wang, MD, Peking University People's Hospital;
Dai-hong Liu, MD, Peking University People's Hospital;
Kai-yan Liu, MD, Peking University People's Hospital;
Lan-ping Xu, MD, Peking University People's Hospital;
Xiao-hui Zhang, MD, Peking University People's Hospital;
Wei Han, MD, Peking University People's Hospital;
Huan Chen, MD, Peking University People's Hospital;
Yu-hong Chen, MD, Peking University People's Hospital;
Feng-rong Wang, MD, Peking University People's Hospital;
Jing-zhi Wang, MD, Peking University People's Hospital;
Hai-xia Fu, MD, Peking University People's Hospital;
Xiao-jun Huang, MD, Peking University People's Hospital
High Risk Allogeneic Hematopoietic Cell Transplant (HCT) Patients with Any Level of Cytomegalovirus (CMV) Viremia Should Be Treated with Antiviral Therapy to Prevent Serious CMV Disease
Lena Winestone, MD, Stanford University;
Rajni Agarwal, MD, Stanford University;
Kenneth I Weinberg, MD, Stanford University School of Medicine;
Matthew Porteus, MD, PhD, Stanford University;
Jennifer Reikes Willert, MD, Rady Children's Hospital/Ucsd;
Michael Amylon, MD, Stanford University Medical Center;
Sandhya Kharbanda, MD, Stanford University
![[Visit Client Website]](images/banner.gif)